Abstract
Among 199 patients treated with thalidomide for multiple myeloma, four thromboses occurred in 49 cases during erythropoietin therapy (prevalence 8.1%; annual rate 7.25%), and another 14 events occurred in patients not on erythropoietin (9.3%; 7.56%). Thus, erythropoietin would seem not to increase the risk of thrombosis of myeloma patients receiving thalidomide.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Anticoagulants / therapeutic use
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use
-
Drug Synergism
-
Erythropoietin / adverse effects*
-
Erythropoietin / pharmacology
-
Erythropoietin / therapeutic use
-
Female
-
Humans
-
Male
-
Middle Aged
-
Multiple Myeloma / complications
-
Multiple Myeloma / drug therapy*
-
Recombinant Proteins
-
Risk
-
Thalidomide / adverse effects*
-
Thalidomide / pharmacology
-
Thalidomide / therapeutic use
-
Thrombosis / chemically induced*
-
Thrombosis / epidemiology
-
Thrombosis / etiology
-
Thrombosis / prevention & control
-
Venous Thrombosis / chemically induced
-
Venous Thrombosis / epidemiology
-
Venous Thrombosis / etiology
-
Venous Thrombosis / prevention & control
-
Warfarin / therapeutic use
Substances
-
Anticoagulants
-
Antineoplastic Agents
-
Recombinant Proteins
-
Erythropoietin
-
Thalidomide
-
Warfarin